Researchers from The Chinese University of Hong Kong and collaborators have discovered a promising target for immunotherapy in non-small-cell lung carcinoma (NSCLC). Their study investigated the regulation of tumor-associated neutrophils (TANs), in particular TGF-β1/Smad3 signaling, and their response to the microenvironment in NSCLC patients.
Caraway Therapeutics Inc. has divulged mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of metabolic diseases, aging, cancer, ciliopathy, neurodegeneration and muscle disorders.
Michigan State University has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer’s disease.
Chiesi Farmaceutici SpA has synthesized pyridazinyl amino derivatives acting as TGF-β receptor type-1 (TGFBR1; ALK5; SKR4; TβR-I) inhibitors reported for be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
PHI-501 is a novel pan-RAF inhibitor being developed for acute myeloid leukemia. Big data, an artificial intelligence (AI)-based drug discovery platform and cell-based investigation identified PHI-501 as potentially useful against melanoma, and researchers from Pharos Ibio Co. Ltd. presented preclinical evaluation of the drug for this new indication.
Researchers from Alpha Cancer Technologies Inc. and affiliated organizations presented data from a study that aimed to assess the effects of ACT-101-maytansinoid conjugates in models of colorectal cancer.
Cyclin-dependent kinases (CDK) are serine/threonine kinases that act as regulatory enzymes involved in cell proliferation. The dysregulation of CDK activity occurs through overexpression of cyclin E1, a binding partner of CDK2, which is observed in several cancers such as high-grade serous ovarian cancer (HGSOC), bladder cancer, gastric cancer and estrogen receptor-positive breast cancer, among others. Selective inhibition of CDK2 may thus be considered a therapeutic approach to regaining cell cycle control.
RSS
